Last Updated:
August 31, 2009



 

  • Petersen EE, Mitchell AA, Carey JC, Werler MW, Louik C, Rasmussen SA, and the National Birth Defects Prevention Study.  Maternal exposure to statins and risk for birth defects: A case-series approach. Am J Med Genet Part A 2008;146A(20):2701–2705. (SEC ppl 494)
  • Bitsko RH, Reefhuis J, Louik C, Werler MM, Feldkamp ML, Waller DK, Frias J, Honein MA, and the National Birth Defects Prevention Study.  Periconceptional use of weight loss products including Ephedra and the association with birth defects.  Birth Defects Res A Clin Mol Teratol 2008;82:553-562. (SEC ppl 489)

  • Toh S, Mitchell AA, Werler MM, Hernández-Díaz S.  Toh et al. respond to “Compromise or Compromising?”.  Am J Epidemiol 2008;167:644-5. (SEC ppl 481)

  • Toh S, Mitchell AA, Werler MM, Hernández-Díaz S.  Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception.  Am J Epidemiol 2008;167:633-640. (SEC ppl 480)
  • Carter TC, Druschel CM, Romitti PA, Bell EM, Werler MM, Mitchell AA, and the National Birth Defects Prevention Study.  Antifungal drugs and the risk of selected birth defects. Am J Obstet Gynecol 2008; 198:191.e1-191.e7. (SEC ppl 483a)

  • Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ, and the National Birth Defects Prevention Study.  Maternal corticosteroid use and orofacial clefts.  Am J Obstet Gynecol 2007;197(6):585.e1-7.  (SEC ppl 477f)

  • Caton AR, Bell EM, Druschel CM, Werler MM, Mitchell AA, Browne ML, McNutt LA, Romitti PA, Olney RS, Correa A, and the National Birth Defects Prevention Study.  Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias.  Birth Defects Res A Clin Mol Teratol 2008;82:34-40. (SEC ppl 479)

  • Browne M, Bell EM, Druschel CM, Gensburg LJ, Mitchell AA, Lin AE, Romitti PA, Correa A, and the National Birth Defects Prevention Study.  Maternal caffeine consumption and risk of cardiovascular malformations.  Birth Defects Res A Clin Mol Teratol 2007;79(7):533-43.  (SEC ppl 469)

  • Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA.  Risk factors for persistent pulmonary hypertension of the newborn.  Pediatrics 2007;120(2);272-282.  (SEC ppl 467)

  • Louik C, Lin AE, Werler MM, Hernández-Díaz S , Mitchell AA. First-trimester use of Selective Serotonin-Reuptake Inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83. (SEC ppl 465)

  • Leeder JS, Mitchell AA. Application of Pharmacogenomic strategies to the study of drug-induced birth defects. Clin Pharmacol Ther 2007;81(4):595-99. (SEC ppl 457)

  • Werler MM. Maternal smoking and undescended testes: Reaching a tipping point. Epidemiology 2007;18:197-198. (SEC ppl 454)

  • Hernández-Díaz S, Schisterman EF, Hernán MA. Response to “The perils of birth weight”. Am J Epidemiol 2006;164:1124-5. (SEC ppl 445)

  • Hernández-Díaz S, Schisterman EF, Hernán MA. The birth weight “paradox” uncovered? Am J Epidemiol 2006;164:1115-20. (SEC ppl 444)

  • Meijer WM, Werler MM, Louik C, Hernández-Díaz S, TW de Jong-van den Berg L, Mitchell AA. Can folic acid protect against congenital heart defects in Down syndrome? Birth Defects Res A Clin Mol Teratol 2006;76(10):714-7. (SEC ppl 433)
  • Louik C, Hernández-Díaz S, Werler MM, Mitchell AA. Nausea and vomiting of pregnancy: Maternal characteristics and risk factors. Paediatr Perinat Epidemiol 2006;20:270-278. (SEC ppl 427)

  • Chambers CD, Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA.  Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.  NEJM 2006;354(6):579-87.  (SEC ppl 419)

  • Mitchell AA. Commentary:  "Prone to sleep, prone to pyloric stenosis?" Epidemiology 2006;17:136-137. (SEC ppl 418)

  • Werler MM, Mitchell AA, Hernández-Díaz S, Honein MA, National Birth Defects Prevention Study. Use of Over-the-Counter Medications during Pregnancy. Am J Obstet Gynecol 2005;193:771-7. (SEC ppl 408)

  • Hernández-Díaz S, Wu XF, Hayes C, Werler MW, Ashok TDS, Badovinac R, Kelsey KT, Mitchell AA. Methylenetetrahydrofolate Reductase C677T Polymorphism and the Risk of Gestational Hypertension. Epidemiology Sept 2005;16(5):628-634. (SEC ppl 407)

  • Mitchell AA. Chapter 32: Studies of Drug-Induced Birth Defect. Pharmacoepidemiology (Strom BL, ed). New York: Wiley, 4th Edition, 2005. (SEC ppl 404)

  • Louik C, Mitchell AA. Post-marketing surveillance using pharmacy-based cohorts: results of a pilot study. Pharmacoepidemiology and Drug Safety 2005;14:289-295. (SEC ppl 399)

  • TW de Jong-van den Berg L, Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Trends and predictors of folic acid awareness and periconceptional use in pregnant women. Am J Obstetrics and Gynecology 2005;192:121-8. (SEC ppl 394)

  • Werler MM, Sheehan JE, Mitchell AA. Gulf war veterans and hemifacial microsomia. Birth Defects Research Part A: Clinical and Molecular Teratology 2005;73:50-52. (SEC ppl 393)

  • Chan KA, Hernández-Díaz S. Pharmacoepidemiology and Rheumatic Disorders. Rheum Dis Clin North Am 2004;30(4):835-50. (SEC ppl 387)

  • Meyer K, Williams P, Hernández-Díaz S, Cnattingius S. Smoking and the risk of oral clefts: exploring the impact of study designs. Epidemiology 2004;15(6):671-8. (SEC ppl 386)

  • Cleves MA, Savell VH Jr., Raj S, Zhao W, Correa A, Werler MM, Hobbs CA, and the National Birth Defects Prevention Study. Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDS), and muscular ventricular septal defects. Birth Defects Research (Part A) 2004;70:107-113. (SEC ppl 390)

  • Werler MM, McCloskey C, Edmonds LD, Olney R, Honein MA, Reefhuis J. Evaluation of an association between Loratadine (Claritin ®) and hypospadias. Data from the National Birth Defects Prevention Study, USA, 1997-2000. MMWR 2004;53(10):219-221. (SEC ppl 389)

  • Werler MM, Sheehan JE, Hayes C, Padwa BL, Mitchell AA, Mulliken JB. Demographic and reproductive factors associated with hemifacial microsomia. Cleft Palate Craniofacial Journal 2004;41:494-500. (SEC ppl 383)

  • Werler MM, Sheehan JE, Hayes C, Mitchell AA, Mulliken JB. Vasoactive exposures, vascular events, and hemifacial microsomia. Birth Defects Research Part A 2004;70:389-95. (SEC ppl 376)

  • Werler MM, Bower C, Payne J, Serna P. Further evidence on potential teratogens: Data from a case-control study in Western Australia. Aust N Z J Obstet Gynaecol 2003;43(6):443-7. (SEC ppl 367)

  • Mitchell AA: Systematic identification of drugs that cause birth defects—A new opportunity. N Engl J Med 2003;349:2556-9. (SEC ppl 362)

  • Hernández-Díaz S and de Abajo FJ. Psychomotor development in children and antenatal psychotropic and anti-epileptic drugs. Commentary. Eur J Epidemiol 2003;18(8):743-4. (SEC ppl 358)

  • Hernández-Díaz S, Hernán MA, Meyer K, Werler MM, Mitchell AA. Case-crossover, case-time-control, and exposed-case-series designs in birth defects epidemiology. Am J Epidemiol 2003;158:385-91. (SEC ppl 357)

  • Meyer KA, Werler MM, Hayes C, Mitchell AA. Low maternal alcohol consumption during pregnancy and oral clefts in offspring: The Slone Birth Defects Study. Birth Defects Research (Part A) 2003;67:509-14. (SEC ppl 355)

  • Werler MM, Sheehan JE, Mitchell AA. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology 2003;14;349-54. (SEC ppl 353)

  • Louik C and Mitchell AA. Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis (Letter to the Editor). Obstet Gynecol 2003;101(4):816. (SEC ppl 352)

  • Waller DK, Tita ATN, Werler MM, Mitchell AA. The association between pre-pregnancy maternal body mass index and the risk of having an infant with a congenital diaphragmatic hernia. Birth Defects Res (Part A) 2003;67:73-76. (SEC ppl 347)

  • Werler MM, Louik C, Mitchell AA. Epidemiologic analysis of maternal factors and amniotic band defects. Birth Defects Res (Part A) 2003;67:68-72. (SEC ppl 346)

  • Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Risk of gestational hypertension in relation to folic acid supplementation during pregnancy. Am J Epidemiol 2002;156:806-12. (SEC ppl 340)

  • Werler MM. Chapter 10: Exposure assessment in studies of oral clefts. In: Wyszynski DF, ed. Cleft lip and palate: from origin to treatment. New York: Oxford University Press 2002;108-116. (SEC ppl 336)

  • Hernández-Díaz S. Iatrogenic legacy from diethylstilbestrol exposure. [Commentary] Lancet 2002;359:1081-2. (SEC ppl 332)

  • Mitchell AA. Infertility treatment - More risks and challenges. [Editorial] N Engl J Med 2002;346:769-70. (SEC ppl 331)

  • Louik C, Werler MM, Mitchell AA. Erythromycin use during pregnancy in relation to pyloric stenosis. Am J Obstet Gynecol 2002;186:288-90. (SEC ppl 330)

  • Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002;155:26-31. (SEC ppl 327)

  • Hernán MA, Hernández-Díaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: An application to birth defects epidemiology. Am J Epidemiol 2002;155:176-84. (SEC ppl 326)

  • Werler M. Additional insights into the etiology of cardiac anomalies [Editorial]. Epidemiology 2001;12:482-4. (SEC ppl 323)

  • Kaufman DW, Rosenberg L, Mitchell AA. Signal generation and clarification: use of case-control data. Pharmacoepidemiol Drug Saf 2001;10:197-203. (SEC ppl 321)

  • Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001;153:961-8. (SEC ppl 315)

  • Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-14. (SEC ppl 307)

  • Mitchell AA. Chapter 42: Special considerations in studies of drug-induced birth defects. In: Strom BL, ed. Pharmacoepidemiology. 3 rd Edition. Chichester, UK: John Wiley and Sons, 2000. (SEC ppl 303)

  • Louik C, Frumkin H, Ellenbecker MJ, Goldman RH, Werler MM, Mitchell AA. Use of a job-exposure matrix to assess occupational exposures in relation to birth defects. J Occup Environ Med 2000;42:693-703. (SEC ppl 300)

  • Werler MM, Mitchell AA. Neural-tube defects. [Letter to the Editor] N Engl J Med 2000;342:1135-6. (SEC ppl 292)

  • Werler MM, Louik C, Mitchell AA. Achieving a public health recommendation for preventing neural tube defects with folic acid. Am J Public Health 1999;89:1637-40. (SEC ppl 282)

  • Lieff S, Olshan AF, Werler M, Strauss RP, Smith J, Mitchell A. Maternal cigarette smoking during pregnancy and risk of oral facial clefts in newborns. Am J Epidemiol 1999;150:683-94. (SEC ppl 281)

  • Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation and birth defects risks. Am J Epidemiol 1999;150:675-82. (SEC ppl 280)

  • Lieff S, Olshan AF, Werler M, Savitz DA, Mitchell AA. Selection bias and the use of controls with malformations in case-control studies of birth defects. Epidemiology 1999;10:238-41. (SEC ppl 271)

  • Mitchell AA. ICSI: Offering hope for a term pregnancy and a healthy child? [Editorial] Br Med J 1997;315:1245-6. (SEC ppl 247)

  • Werler MM. Teratogen Update: Smoking and reproductive outcomes. Teratology 1997;55:382-8. (SEC ppl 240)

  • Werler MM, Cragan JD, Wasserman CR, Shaw GM, Erickson JD, Mitchell AA. Multivitamin supplementation and multiple births. Am J Med Genet 1997;71:93-6. (SEC ppl 237)

  • Hayes C, Werler MM, Willett WC, Mitchell AA. Case-control study of periconceptional folic acid supplementation and oral clefts. Am J Epidemiol 1996;143:1229-34. (SEC ppl 219)

  • Werler MM, Louik C, Shapiro SS, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. JAMA 1996;275:1089-92. (SEC ppl 215)

  • Werler MM, Mitchell AA. More on folic acid (re: Beresford). [Letter to Editor] Am J Public Health 1995;85:269. (SEC ppl 199)

  • Mitchell AA, Werler MM, Shapiro S. A response to the commentary "Should we consider a subject's knowledge of the etiologic hypothesis in the analysis of case-control studies?" Am J Epidemiol 1995;141:297-8. (SEC ppl 198)

  • Mitchell AA. Special considerations in studies of drug-induced birth defects. In: Strom BL, ed. Pharmacoepidemiology. 2nd ed. 1994;595-608. (SEC ppl 190)

  • Werler MM, Louik C, Shapiro S, Mitchell AA. Ovulation induction and risk of neural tube defects. Lancet 1994;344:445-6. (SEC ppl 188)

  • Werler MM, Mitchell AA. Case-control study of vitamin supplementation and neural tube defects: Consideration of potential confounding by lifestyle factors. In: Keen CL, Bendich A, Willhite CC, eds. Maternal nutrition and pregnancy outcome. Ann NY Acad Sci 1993;678:276-83. (SEC ppl 171)

  • Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993;269:1257-61. (SEC ppl 168)

  • Mitchell AA, Werler MM, Shapiro S. Commentary: Analyses and reanalyses of epidemiologic data: Learning lessons and maintaining perspective. Teratology 1992;46:209-11. (SEC ppl 160)

  • Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992;45:361-7. (SEC ppl 159)

  • Werler MM, Mitchell AA, Shapiro S. Demographic, reproductive, medical and environmental factors in relation to gastroschisis. Teratology 1992;45:353-60. (SEC ppl 158)

  • Mitchell AA. Oral retinoids: What should the prescriber know about their teratogenic hazards among women of child-bearing potential? Drug Saf 1992;7:79-85. (SEC ppl 157)

  • Werler MM, Mitchell AA, Rosenberg L, Lammer EJ. Maternal alcohol use in relation to selected birth defects. Am J Epidemiol 1991;134:691-8. (SEC ppl 149)

  • Mitchell AA. Teratogens and the Dermatologist: New Knowledge, Responsibilities, and Oppurtunities. Arch Dermatol 1991;127:399-401. (SEC ppl 141)

  • Werler MM, Lammer EJ, Rosenberg L, Mitchell AA. Maternal vitamin A supplementation in relation to selected birth defects. Teratology 1990;42:497-503. (SEC ppl 134)

  • Werler MM, Lammer EJ, Rosenberg L, Mitchell AA. Maternal cigarette smoking during pregnancy in relation to oral clefts. Am J Epidemiol 1990;132:926-32. (SEC ppl 133)

  • Werler MM, Mitchell AA, Shapiro S. First trimester aspirin use in relation to congenital cardiac defects. N Engl J Med 1989;321:1639-41. (SEC ppl 120)

  • Mitchell AA. Slone Epidemiology Unit Birth Defects Study. The Genetic Resource ( Mass. Dept. Public Health) 1988;4:31-2. (SEC ppl 108)

  • Louik C, Mitchell AA, Werler MM, Hanson J, Shapiro S. Maternal exposure to spermicides in relation to certain birth defects. N Engl J Med 1987;317:474-8. (SEC ppl 98)

  • Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986;123:670-6. (SEC ppl 81)

  • Mitchell AA, Schwingl PJ, Rosenberg L, Louik C, Shapiro S. Birth defects in relation to Bendectin use in pregnancy: 2. Pyloric stenosis. Am J Obstet Gynecol 1983;147:737-42. (SEC ppl 59)

  • Rosenberg L, Mitchell AA, Parsells J, Pashayan H, Louik C, Shapiro S. Oral clefts in relation to diazepam use during pregnancy. N Engl J Med 1983;309:1282-5. (SEC ppl 58)

  • Shapiro S, Slone D, Heinonen OP, Kaufman DW, Rosenberg L, Mitchell AA, Helmrich SP. Birth defects in relation to vaginal spermicides. JAMA 1982;247:2381-4. (SEC ppl 45)

  • Rosenberg L, Mitchell AA, Shapiro S and Slone D. Selected birth defects in relation to caffeine-containing beverages. JAMA 1982;247:1429-32. (SEC ppl 43)

  • Mitchell AA, Rosenberg L, Shapiro S, Slone D. Birth defects related to use of Bendectin in pregnancy: 1. Oral clefts and cardiac defects. JAMA 1981;245:2311-14. (SEC ppl 38)

  • Slone D, Shapiro S, Mitchell AA. Strategies for studying the effects of the antenatal chemical environment on the fetus. In: Schwarz and Yaffe eds. Drug and chemical risks to the fetus and newborn. New York : Alan R. Liss, Inc., 1980. (SEC ppl 24)


Manuscripts in Press

  • Toh S, Mitchell AA, Louik C, Werler MM Chambers CD, Hernandez-Diaz S. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol, in press.



Quick-Links

Project Information
Participant Information
Study Sites
Contact Information
Publications